September 2024 in “Journal of the American Academy of Dermatology” Baricitinib 4 mg is effective and safe for treating severe alopecia areata.
April 2026 in “Zenodo (CERN European Organization for Nuclear Research)” The model improves understanding of androgen interactions by focusing on signal intensity and system capacity.
October 2023 in “Journal of the Endocrine Society” Joint replacement surgery normalized high alkaline phosphatase levels in a patient with severe osteoarthritis.
November 2025 in “Figshare” SQSTM1 is linked to increased risk of alopecia areata.
128 citations
,
February 2016 in “British Journal of Dermatology” Alopecia areata significantly lowers the quality of life, especially in emotional and mental health aspects.
37 citations
,
January 2011 in “Annals of Dermatology” ALA-photodynamic therapy helps reduce acne by causing acne cell death and lowering certain skin protein levels.
6 citations
,
March 2024 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib is effective for long-term treatment of severe alopecia areata.
September 2025 in “Value in Health” August 2025 in “Marine Drugs” The new composite material is safe and has anticoagulant properties.
March 2026 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib is being tested for safety and effectiveness in young children with severe alopecia areata.
56 citations
,
April 2007 in “Journal der Deutschen Dermatologischen Gesellschaft” Minoxidil works better for female hair loss than alfatradiol, both safe.
4 citations
,
July 2024 in “Pharmacology Research & Perspectives” Ritlecitinib is safe and may effectively treat alopecia areata.
December 2023 in “Journal of health and rehabilitation research” Oral Apremilast effectively treats alopecia areata in most patients.
November 2025 in “SKIN The Journal of Cutaneous Medicine” Baricitinib significantly regrows hair in teens with severe alopecia areata.
April 2024 in “Frontiers in medicine” Alopecia Areata significantly lowers quality of life and current treatments are inadequate, highlighting a need for better therapies and standardized treatment protocols.
March 2025 in “Journal of the European Academy of Dermatology and Venereology” Baricitinib effectively reduces hair loss in alopecia areata and is well-tolerated.
February 2026 in “The Journal of Dermatology” Ritlecitinib effectively regrows scalp, eyebrow, and eyelash hair in Asians with alopecia areata and is safe.
Higher air pollution increases the risk of alopecia areata.
May 2023 in “Reactions Weekly” January 2013 in “Reactions Weekly”
January 2025 in “SKIN The Journal of Cutaneous Medicine” Baricitinib significantly regrows hair in severe alopecia areata patients.
3 citations
,
July 2025 in “Clinical and Experimental Dermatology” Ritlecitinib may be more effective for severe alopecia areata than conventional treatments.
November 2025 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib 50 mg effectively promotes and sustains hair regrowth in alopecia areata patients.
1 citations
,
August 2023 in “International Journal of Surgery Case Reports” Using titanium mesh and thigh tissue is effective for complex scalp reconstruction.
19 citations
,
May 2014 in “Molecules” Avicequinone C, a compound found in the Avicennia marina plant, can reduce hair loss by inhibiting a hormone linked to androgenic alopecia.
95 citations
,
July 2016 in “Journal of The American Academy of Dermatology” People with alopecia areata, a skin disease, generally have a poor quality of life, especially if more of their scalp is affected.
34 citations
,
August 2002 in “British Journal of Dermatology” ALA-PDT is effective and safe for chronic X-ray dermatitis, providing complete or partial remission.
January 2017 in “DOAJ (DOAJ: Directory of Open Access Journals)” Hair loss from alopecia areata and androgenetic alopecia moderately affects the quality of life, especially in younger patients and those with long-term hair loss, impacting both their physical and emotional well-being.
April 2023 in “Journal of Investigative Dermatology” Alopecia areata significantly affects emotional well-being and quality of life, especially in younger adults.
June 2023 in “International Journal of Research in Medical Sciences” Two brothers from Bangladesh were diagnosed with X-linked adrenoleukodystrophy, showing neurological and adrenal symptoms.